Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Jan 29;286(6362):338–340. doi: 10.1136/bmj.286.6362.338

HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

M J Garlepp, R L Dawkins, F T Christiansen
PMCID: PMC1546897  PMID: 6402089

Abstract

Antibodies to the acetylcholine receptor and HLA antigens have been studied in patients with myasthenia gravis occurring in association with penicillamine treatment. The properties of the antiacetylcholine receptor in these patients differed from those in patients with idiopathic myasthenia gravis in terms of specificity and affinity. These patients had an increased prevalence of HLA Bw35 and DR1 compared to controls and a decreased frequency of B8 and DR3 compared to patients with idiopathic myasthenia gravis. Likewise, they had a decreased frequency of DR4 compared to patients with rheumatoid arthritis. These data provide supportive evidence for a role for penicillamine in the induction of myasthenia gravis in genetically predisposed individuals.

Full text

PDF
338

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers J. W., Hodach R. J., Kimmel D. W., Treacy W. L. Penicillamine-associated myasthenia gravis. Neurology. 1980 Nov;30(11):1246–1249. doi: 10.1212/wnl.30.11.1246. [DOI] [PubMed] [Google Scholar]
  2. Batchelor J. R., Welsh K. I., Tinoco R. M., Dollery C. T., Hughes G. R., Bernstein R., Ryan P., Naish P. F., Aber G. M., Bing R. F. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1980 May 24;1(8178):1107–1109. doi: 10.1016/s0140-6736(80)91554-8. [DOI] [PubMed] [Google Scholar]
  3. Bray J. J., Drachman D. B. Binding affinities of anti-acetylcholine receptor autoantibodies in myasthenia gravis. J Immunol. 1982 Jan;128(1):105–110. [PubMed] [Google Scholar]
  4. Dawkins R. L., Christiansen F. T., Kay P. H., Garlepp M., McCluskey J., Hollingsworth P. N., Zilko P. J. Disease associations with complotypes, supratypes and haplotypes. Immunol Rev. 1983;70:5–22. doi: 10.1111/j.1600-065x.1983.tb00707.x. [DOI] [PubMed] [Google Scholar]
  5. Dawkins R. L., Garlepp M. J., McDonald B. L., Williamson J., Zilko P. J., Carrano J. Myasthenia gravis and D-penicillamine. J Rheumatol Suppl. 1981 Jan-Feb;7:169–174. [PubMed] [Google Scholar]
  6. Garlepp M. J., Kay P. H., Dawkins R. L., Bucknall R. C., Kemp A. Cross-reactivity of anti-acetylcholine receptor autoantibodies. Muscle Nerve. 1981 Jul-Aug;4(4):282–288. doi: 10.1002/mus.880040404. [DOI] [PubMed] [Google Scholar]
  7. Keesey J., Novom S. HLA antigens in pencillamine-induced myasthenia gravis. Neurology. 1979 Apr;29(4):528–529. doi: 10.1212/wnl.29.4.528-a. [DOI] [PubMed] [Google Scholar]
  8. Masters C. L., Dawkins R. L., Zilko P. J., Simpson J. A., Leedman R. J. Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies. Am J Med. 1977 Nov;63(5):689–694. doi: 10.1016/0002-9343(77)90153-x. [DOI] [PubMed] [Google Scholar]
  9. Pirskanen R. On the significance of HL-A and LD antigens in myasthenia gravis. Ann N Y Acad Sci. 1976;274:451–460. doi: 10.1111/j.1749-6632.1976.tb47706.x. [DOI] [PubMed] [Google Scholar]
  10. Russell A. S., Lindstrom J. M. Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor. Neurology. 1978 Aug;28(8):847–849. doi: 10.1212/wnl.28.8.847. [DOI] [PubMed] [Google Scholar]
  11. Schiff B., Mizrachi Y., Orgad S., Yaron M., Gazit E. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis. 1982 Aug;41(4):403–404. doi: 10.1136/ard.41.4.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Torres C. F., Griggs R. C., Baum J., Penn A. S. Penicillamine-induced myasthenia gravis in progressive systemic sclerosis. Arthritis Rheum. 1980 Apr;23(4):505–508. doi: 10.1002/art.1780230414. [DOI] [PubMed] [Google Scholar]
  13. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clin Exp Immunol. 1982 Aug;49(2):266–272. [PMC free article] [PubMed] [Google Scholar]
  14. Woodrow J. C., Nichol F. E., Zaphiropoulos G. DR antigens and rheumatoid arthritis: a study of two populations. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1287–1288. doi: 10.1136/bmj.283.6302.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zilko P. J., Dawkins R. L., Holmes K., Witt C. Genetic control of suppressor lymphocyte function in myasthenia gravis: relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies. Clin Immunol Immunopathol. 1979 Oct;14(2):222–230. doi: 10.1016/0090-1229(79)90143-0. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES